Advanced search
Publication Cover
Infection and Drug Resistance Volume 7, 2014 - Issue
Submit an article Journal homepage
83
Views
10
CrossRef citations to date
0
Altmetric
Review

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia

Ethan Rubinstein1 University of Manitoba, Winnipeg, MB, CanadaCorrespondence[email protected]
,
Martin E Stryjewski2 Department of Medicine, Section of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina
&
Steven L Barriere3 Theravance, Inc., South San Francisco, CA, USA
Pages 129-135 | Published online: 20 May 2014

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Liapikou Adamantia & Torres Antoni. (2016) Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia. Expert Opinion on Drug Metabolism & Toxicology 12:7, pages 803-812.
Read now
Obinna N Nnedu & George A Pankey. (2015) Update on the emerging role of telavancin in hospital-acquired infections. Therapeutics and Clinical Risk Management 11, pages 605-610.
Read now

Articles from other publishers (8)

Wissal Jame, Bilgen Basgut & Abdikarim Abdi. (2021) Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis. PLOS ONE 16:11, pages e0260539.
Crossref
Thiago Henrique da Silva, Thais Massetti, Talita Dias da Silva, Laercio da Silva Paiva, Denise Cardoso Ribeiro Papa, Carlos Bandeira de Mello Monteiro, Fatima Aparecida Caromano, Mariana Callil Voos & Lucas Del Sarto Silva. (2018) Influence of severity of traumatic brain injury at hospital admission on clinical outcomes. Fisioterapia e Pesquisa 25:1, pages 3-8.
Crossref
Michael A. PfallerHelio S. SaderRobert K. FlammMariana CastanheiraJennifer I. SmartRodrigo E. Mendes. (2017) In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions . Microbial Drug Resistance 23:6, pages 718-726.
Crossref
Junlan Chuan, Yuan Zhang, Xia He, Yuxuan Zhu, Lei Zhong, Dongke Yu & Hongtao Xiao. (2016) Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?. Frontiers in Pharmacology 7.
Crossref
Adamantia Liapikou, Katerina Dimakou & Michael Toumbis. (2016) Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience . Therapeutic Advances in Respiratory Disease 10:4, pages 368-378.
Crossref
Christian E. Sandrock & Andrew F. Shorr. (2015) The Role of Telavancin in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. Clinical Infectious Diseases 61:suppl 2, pages S79-S86.
Crossref
Rodrigo E. Mendes, David J. Farrell, Helio S. Sader, Robert K. Flamm & Ronald N. Jones. (2015) Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method. Antimicrobial Agents and Chemotherapy 59:1, pages 702-706.
Crossref
Saira B. Chaudhry. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 293 305 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.